<DOC>
	<DOCNO>NCT01839929</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tacrolimus modify release formulation Advagraf速 conversion Prograf速 stable kidney transplant patient .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy ADVAGRAF ( Tacrolimus Modified Release Formulation ) Kidney Transplant Patients Who Were Treated With PROGRAF</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Patients receive kidney transplant least 12 month ago prior enrollment . 2 . Patients take unchanged dosage Prograf速 remain stable serum level tacrolimus least 12 week prior enrollment . 3 . Patients keep unchanged immunosuppressive therapy ( combination therapy ) least 12 week prior enrollment . 4 . Female patient childbearing potential must negative urine serum pregnancy test prior enrollment , agree deliberate prevention conception trial . 5 . Patients consider clinically stable observer 's judgment . 6 . Patients must understand purpose risk participate trial sign write consent . 1 . Patients previously receive organ transplant kidney . 2 . Patients acute transplant rejection within 12 week , acute transplant rejection require antilymphocyte therapy within 24 week prior enrollment . 3 . Patients newly diagnose malignant tumor organ transplant patient treat completely basal squamous cell carcinoma skin except . 4 . Patients know hypersensitivity Prograf速 tacrolimus . 5 . Patients whose medical condition able interfere study objective . 6 . Patients risk drug abuse mental disorder communicate difficulty observer . 7 . Patients participate another clinical trial , treat drug clinical trial within 28 day prior enrollment . 8 . Patients take prohibited combination agent within 28 day prior enrollment . 9 . Patients pregnant lactate . 10 . Patient HIVpositive . 11 . Patients able keep scheduled visit . 12 . Patients whose GFR ( MDRD ) level &lt; 30 mL/min . 13 . Patients condition 'Creeping creatinine ( defined 20 % increase within 6 month prior enrollment ) 14 . Patients whose SGPT/AST and/or SGOT/ALT level elevate great 2 time upper value normal range . 15 . Patients FSGS MPGN Type II underlie disease . 16 . Patients cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>tacrolimus</keyword>
	<keyword>immunosuppressant</keyword>
	<keyword>FK506</keyword>
</DOC>